Details of the Drug

General Information of Drug (ID: DMPMYE8)

Drug Name

Miconazole

Synonyms

Dactarin; MCZ; Miconazol; Miconazolo; Miconazolum; Micozole; Minostate; Monistat; Vusion; Zimycan; Daktarin IV; Miconasil Nitrate; Miconazole nitrate salt; Miconazolo [DCIT]; Monistat IV; MJR 1762; Miconazole 3; Miconazole 3 Combination Pack; Miconazole 7 Combination Pack; Monazole 7; Monistat 1 Combination Pack; Monistat 3 Vaginal Ovules; Monistat 5 Tampon; Monistat 7 Vaginal Suppositories; R 18134; Aflorix(nitrate); Albistat(nitrate); Andergin(nitrate); Conofite(nitrate); Daktarin (TN); Femizol (TN); Femizol-M; Florid(nitrate); Lotrimin AF(nitrate); Micantin (nitrate); Micatin (TN); Miconazex (TN); Miconazol [INN-Spanish]; Miconazole-7; Miconazolum [INN-Latin]; Monista (nitrate); Monistat (TN); Monistat 3 Dual-Pak; Monistat 7 Dual-Pak; Monistat Dual-PAK; Monistat iv (TN); Monistat-Derm; Novo-Miconazole Vaginal Ovules; Epi-Monistat(nitrate); Gyno-Daktar(nitrate); Monistat-Derm (TN); R-14,889; Miconazole (JP15/USP/INN); Miconazole [USAN:BAN:INN:JAN]; Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)-(9CI); Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-(9CI); (+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole; 1-[2,4-Dichloro-beta-([2,4-dichloro-benzyl]oxy)phenethyl]imidazole; 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole; 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole; 1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole; 1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole

Indication

Disease Entry	ICD 11	Status	REF
Fungal infection	1F29-1F2F	Approved	[1], [2]

Therapeutic Class

Antifungal Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

416.1

Topological Polar Surface Area (xlogp)

5.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 55.2 +/- 35.1 mgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 15.1 +/- 16.2 mg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 7 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 9.48 mL/min/kg [5]
Elimination: Miconazole is excreted through both urine and feces, and less than 1% of unchanged miconazole is recovered in urine [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 24 hours [3]
Metabolism: The drug is metabolized via the liver [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 144.18326 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.08% [5]
Vd: The volume of distribution (Vd) of drug is 95,546 L [7]
Water Solubility: The ability of drug to dissolve in water is measured as 0.89 mg/mL [4]

Chemical Identifiers

Formula: C18H14Cl4N2O
IUPAC Name: 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
Canonical SMILES: C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl
InChI: InChI=1S/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2
InChIKey: BYBLEWFAAKGYCD-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4189
ChEBI ID: CHEBI:82892
CAS Number: 22916-47-8
DrugBank ID: DB01110
TTD ID: D00AXJ
VARIDT ID: DR00477
INTEDE ID: DR1084
ACDINA ID: D00429

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Candida Cytochrome P450 51 (Candi ERG11)	TTTSOUD	CP51_CANAL	Modulator	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Miconazole (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Midostaurin	DMI6E0R	Moderate	Decreased metabolism of Miconazole caused by Midostaurin mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[26]
Gilteritinib	DMWQ4MZ	Moderate	Decreased metabolism of Miconazole caused by Gilteritinib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[27]
Oliceridine	DM6MDCF	Moderate	Decreased metabolism of Miconazole caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[28]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Miconazole caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[28]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Miconazole caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[29]
Budesonide	DMJIBAW	Moderate	Decreased metabolism of Miconazole caused by Budesonide mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[30]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Miconazole caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[31]
Cariprazine	DMJYDVK	Moderate	Decreased metabolism of Miconazole caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[32]
Pexidartinib	DMS2J0Z	Major	Decreased metabolism of Miconazole caused by Pexidartinib mediated inhibition of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[33]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Miconazole caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[34]
Esterified estrogens	DM9KZDO	Moderate	Decreased metabolism of Miconazole caused by Esterified estrogens mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[35]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Miconazole caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Quinestrol	DMJ6H1Z	Moderate	Decreased metabolism of Miconazole caused by Quinestrol mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[35]
Cabazitaxel	DMPAZHC	Moderate	Decreased metabolism of Miconazole caused by Cabazitaxel mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[36]
Bosutinib	DMTI8YE	Moderate	Decreased metabolism of Miconazole caused by Bosutinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Macitentan	DMP79A1	Moderate	Decreased metabolism of Miconazole caused by Macitentan mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[37]
PF-04449913	DMSB068	Moderate	Decreased metabolism of Miconazole caused by PF-04449913 mediated inhibition of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[38]
Indacaterol	DMQJHR7	Minor	Decreased metabolism of Miconazole caused by Indacaterol mediated inhibition of CYP450 enzyme.	Chronic obstructive pulmonary disease [CA22]	[39]
Anisindione	DM2C48U	Major	Decreased metabolism of Miconazole caused by Anisindione mediated inhibition of CYP450 enzyme.	Coagulation defect [3B10]	[40]
Drospirenone	DM1A9W3	Moderate	Decreased metabolism of Miconazole caused by Drospirenone mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[35]
Levonorgestrel	DM1DP7T	Moderate	Decreased metabolism of Miconazole caused by Levonorgestrel mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[35]
Ulipristal	DMBNI20	Minor	Decreased metabolism of Miconazole caused by Ulipristal mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[27]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Miconazole caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[41]
Rivaroxaban	DMQMBZ1	Moderate	Decreased metabolism of Miconazole caused by Rivaroxaban mediated inhibition of CYP450 enzyme.	Deep vein thrombosis [BD71]	[42]
Vilazodone	DM4LECQ	Moderate	Decreased metabolism of Miconazole caused by Vilazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[43]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Miconazole caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[44]
Escitalopram	DMFK9HG	Minor	Decreased metabolism of Miconazole caused by Escitalopram mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[45]
Polatuzumab vedotin	DMF6Y0L	Moderate	Decreased metabolism of Miconazole caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[46]
[3H]estrone-3-sulphate	DMGPF0N	Moderate	Decreased metabolism of Miconazole caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme.	Discovery agent [N.A.]	[47]
Ospemifene	DMC4GEI	Moderate	Decreased metabolism of Miconazole caused by Ospemifene mediated inhibition of CYP450 enzyme.	Dyspareunia [GA12]	[48]
Fosphenytoin	DMOX3LB	Moderate	Decreased metabolism of Miconazole caused by Fosphenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[49]
Solifenacin	DMG592Q	Moderate	Decreased metabolism of Miconazole caused by Solifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[50]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Miconazole caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[51]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Miconazole caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[42]
Avapritinib	DMK2GZX	Moderate	Decreased metabolism of Miconazole caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[27]
Colchicine	DM2POTE	Moderate	Decreased metabolism of Miconazole caused by Colchicine mediated inhibition of CYP450 enzyme.	Gout [FA25]	[28]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Miconazole caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[52]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Miconazole caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[52]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Miconazole caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Dolutegravir	DMCZGRE	Minor	Decreased metabolism of Miconazole caused by Dolutegravir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[54]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Miconazole caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Miconazole caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[55]
BMS-201038	DMQTAGO	Moderate	Decreased metabolism of Miconazole caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[28]
Aliskiren	DM1BV7W	Moderate	Decreased metabolism of Miconazole caused by Aliskiren mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[56]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Miconazole caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[29]
Tolvaptan	DMIWFRL	Moderate	Decreased metabolism of Miconazole caused by Tolvaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[28]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Miconazole caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[27]
Retapamulin	DM9JXB7	Minor	Decreased metabolism of Miconazole caused by Retapamulin mediated inhibition of CYP450 enzyme.	Impetigo [1B72]	[57]
Lesinurad	DMUR64T	Moderate	Decreased metabolism of Miconazole caused by Lesinurad mediated inhibition of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[58]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Miconazole caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[42]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Miconazole caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[59]
ITI-007	DMUQ1DO	Moderate	Decreased metabolism of Miconazole caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[60]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Miconazole caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[61]
Brigatinib	DM7W94S	Moderate	Decreased metabolism of Miconazole caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[42]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Miconazole caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[62]
PF-06463922	DMKM7EW	Moderate	Decreased metabolism of Miconazole caused by PF-06463922 mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[63]
Osimertinib	DMRJLAT	Moderate	Decreased metabolism of Miconazole caused by Osimertinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[64]
Artemether	DM48QOT	Moderate	Decreased metabolism of Miconazole caused by Artemether mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[28]
Halofantrine	DMOMK1V	Moderate	Decreased metabolism of Miconazole caused by Halofantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[28]
GDC-0199	DMH0QKA	Moderate	Decreased metabolism of Miconazole caused by GDC-0199 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[42]
Acalabrutinib	DM7GCVW	Moderate	Decreased metabolism of Miconazole caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[65]
Ibrutinib	DMHZCPO	Moderate	Decreased metabolism of Miconazole caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[66]
Ponatinib	DMYGJQO	Moderate	Decreased metabolism of Miconazole caused by Ponatinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[67]
Ubrogepant	DM749I3	Moderate	Decreased metabolism of Miconazole caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[68]
Flibanserin	DM70DTN	Moderate	Decreased metabolism of Miconazole caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[69]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Miconazole caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[70]
Romidepsin	DMT5GNL	Moderate	Decreased metabolism of Miconazole caused by Romidepsin mediated inhibition of CYP450 enzyme.	Mycosis fungoides [2B01]	[71]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Miconazole caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[28]
Ruxolitinib	DM7Q98D	Minor	Decreased metabolism of Miconazole caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[27]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Miconazole caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[28]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Miconazole caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[72]
Levomethadyl Acetate	DM06HG5	Moderate	Decreased metabolism of Miconazole caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[28]
S-297995	DM26IH8	Moderate	Decreased metabolism of Miconazole caused by S-297995 mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[27]
Olaparib	DM8QB1D	Moderate	Decreased metabolism of Miconazole caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[73]
Istradefylline	DM20VSK	Moderate	Decreased metabolism of Miconazole caused by Istradefylline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[28]
Pimavanserin	DMR7IVC	Moderate	Decreased metabolism of Miconazole caused by Pimavanserin mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[74]
Ergonovine	DM0VEC1	Moderate	Decreased metabolism of Miconazole caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[75]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Miconazole caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[28]
Enzalutamide	DMGL19D	Moderate	Decreased metabolism of Miconazole caused by Enzalutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[76]
Darolutamide	DMV7YFT	Minor	Decreased metabolism of Miconazole caused by Darolutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[77]
Silodosin	DMJSBT6	Moderate	Decreased metabolism of Miconazole caused by Silodosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[78]
Dutasteride	DMQ4TJK	Moderate	Decreased metabolism of Miconazole caused by Dutasteride mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[79]
Ambrisentan	DMD1QXW	Minor	Decreased metabolism of Miconazole caused by Ambrisentan mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[80]
Everolimus	DM8X2EH	Moderate	Decreased metabolism of Miconazole caused by Everolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[28]
Axitinib	DMGVH6N	Moderate	Decreased metabolism of Miconazole caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[27]
Temsirolimus	DMS104F	Moderate	Decreased metabolism of Miconazole caused by Temsirolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[81]
Ciclesonide	DM2NA4K	Moderate	Decreased metabolism of Miconazole caused by Ciclesonide mediated inhibition of CYP450 enzyme.	Respiratory system disease [CB40-CB7Z]	[82]
Upadacitinib	DM32B5U	Moderate	Decreased metabolism of Miconazole caused by Upadacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[28]
Tofacitinib	DMBS370	Moderate	Decreased metabolism of Miconazole caused by Tofacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[28]
Dexamethasone	DMMWZET	Moderate	Decreased metabolism of Miconazole caused by Dexamethasone mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[83]
Quetiapine	DM1N62C	Moderate	Decreased metabolism of Miconazole caused by Quetiapine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[84]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Miconazole caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[85]
Iloperidone	DM6AUFY	Moderate	Decreased metabolism of Miconazole caused by Iloperidone mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[28]
LDE225	DMM9F25	Moderate	Decreased metabolism of Miconazole caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[86]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Miconazole caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[42]
Docetaxel	DMDI269	Moderate	Decreased metabolism of Miconazole caused by Docetaxel mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[87]
Trabectedin	DMG3Y89	Moderate	Decreased metabolism of Miconazole caused by Trabectedin mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[27]
Armodafinil	DMGB035	Minor	Decreased metabolism of Miconazole caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[42]
LEE011	DMMX75K	Moderate	Decreased metabolism of Miconazole caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[42]
Taxol	DMUOT9V	Moderate	Decreased metabolism of Miconazole caused by Taxol mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[88]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Miconazole caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[89]
Apixaban	DM89JLN	Moderate	Decreased metabolism of Miconazole caused by Apixaban mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[27]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Miconazole caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[27]
Cabozantinib	DMIYDT4	Moderate	Decreased metabolism of Miconazole caused by Cabozantinib mediated inhibition of CYP450 enzyme.	Thyroid cancer [2D10]	[90]
Tolbutamide	DM02AWV	Major	Decreased metabolism of Miconazole caused by Tolbutamide mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[91]
Saxagliptin	DMGXENV	Moderate	Decreased metabolism of Miconazole caused by Saxagliptin mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[27]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Miconazole caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[28]
-----------


⏷ Show the Full List of 107 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Miconazole 50 mg tablet	50 mg	Buccal Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2449).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076773.
3	FDA Approved Drug Products: Oravig (miconazole) buccal tablet
4	BDDCS applied to over 900 drugs
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Stevens RE, Konsil J, Verrill SS, Roy P, Desai PB, Upmalis DH, Cone FL: Bioavailability study of a 1200 mg miconazole nitrate vaginal ovule in healthy female adults. J Clin Pharmacol. 2002 Jan;42(1):52-60. doi: 10.1177/0091270002042001006.
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9	Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
10	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19	A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6.
20	Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
21	Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9.
22	Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.
23	Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7.
24	Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6.
25	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603.
26	Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
27	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
28	Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
29	Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
30	Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
31	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
32	Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
33	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
34	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
35	Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9. [PMID: 2547410]
36	Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
37	Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
38	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
39	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
40	Ariyaratnam S, Thakker NS, Sloan P, Thornhill MH "Potentiation of warfarin anticoagulant activity by miconazole oral gel." BMJ 314 (1997): 349. [PMID: 9040331]
41	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
42	Cerner Multum, Inc. "Australian Product Information.".
43	Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
44	Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
45	Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
46	Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
47	Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488]
48	Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
49	Rolan PE, Somogyi AA, Drew MJ, et al "Phenytoin intoxication during treatment with parenteral miconazole." Br Med J (Clin Res Ed) 287 (1983): 1760. [PMID: 6416579]
50	Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
51	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
52	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
53	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
54	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
55	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
56	Canadian Pharmacists Association.
57	Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
58	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
59	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
60	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
61	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
62	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
63	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
64	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
65	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
66	Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
67	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
68	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
69	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
70	Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
71	Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
72	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
73	Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
74	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
75	Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207. [PMID: 9145904]
76	Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
77	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
78	Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
79	Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
80	Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
81	Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
82	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
83	Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease." Clin Pharmacokinet 43 (2004): 803-21. [PMID: 15355126]
84	DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
85	Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
86	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
87	Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
88	Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
89	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
90	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
91	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]